BONE MARROW FAILURE CLINICAL RESEARCH CENTER

骨髓衰竭临床研究中心

• 批准号: 7622817
• 负责人: Jaroslaw P Maciejewski
• 金额: $ 40.48万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-01 至 2008-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7622817
• 关键词: Algorithms; Anemia; Aplastic Anemia; Biological Assay; Blood Cells; Cancer Center; Caring; Cell Lineage; Clinic; Clinical Research; Clinical Trials; Collaborations; Community Physician; Computer Retrieval of Information on Scientific Projects Database; Data; Diagnosis; Diagnostic; Disease; Dysmyelopoietic Syndromes; Education; Education and Outreach; Enrollment; Failure; Follow-Up Studies; Foundations; Functional disorder; Funding; Grant; Hematopoietic; Immune; Institution; International; Laboratories; Medical; Medical center; Numbers; Outcome; Pancytopenia; Patients; Physicians; Positioning Attribute; Production; Pure Red-Cell Aplasia; Rare Diseases; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Site; Source; Specialized Center; Standards of Weights and Measures; Stem cells; Technology; Testing; Translational Research; Transplantation; Treatment Protocols; United States National Institutes of Health; bone; chronic T-cell leukemia; collaborative trial; cytopenia; data management; diagnostic accuracy; experience; improved; novel; patient advocacy group; patient oriented; post-doctoral training; progenitor; rat Piga protein; size; success

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): Idiopathic bone marrow failure states and cytopenias (IBMFS&C) are rare disorders characterized by hematopoietic progenitor or stem cell failure resulting in deficient production of one, or all, blood cell lineages. Immune pathophysiology is a unifying factor in many cases of all these diseases. Prior collaborative trials have led to the improvement of effective medical therapy for aplastic anemia (AA), but ongoing multi-center studies are required to advance further the outcome for AA and especially the other bone IBMFS for which few useful treatment options exist. Here, we propose formation of the IBMFS&C Rare Disease Clinical Research Center (RDCRC) at The Cleveland Clinic Foundation (CCF) Cancer Center, encompassing a consortium of several specialized centers, patient advocacy group, and data and a collaboration with a data technology coordinating center (DTCC). The IBMFS&C RDCRC will focus on AA, paroxysmal nocturnal hemoglobinuria, single-lineage cytopenias including large granular lymphocyte leukemia and pure red cell aplasia, and various myelodysplastic syndromes. This application presents a multi-targeted approach to improving the medical therapy for IBMFS&C that includes: 1) implementing treatment algorithms for each IBMFS that define standards of care, 2) systematically evaluating novel laboratory assays that may improve the diagnostic accuracy or understanding of pathophysiologic mechanisms, 3) enrolling patients into a longitudinal follow-up study to correlate new and established diagnostic variables with outcome, 4) comparing medical and transplant approaches for each relevant disorder, 5) developing experimental treatment protocols for disease subsets currently without good treatment options or without a standard treatment approach, 6) training of post-doctoral fellows to develop clinical trials and translational research projects for the IBMFS&C, 7) educating community physicians in the diagnosis and management of the IBMFS&C, and 8) improving outreach, education and referral resources for patients and physicians, in collaboration with the Aplastic Anemia & MDS International Foundation (AAMDSIF). Due to the expertise of the PI, together with the experience and size of CCF CC, CCF uniquely is positioned to serve as an RDCRC in IBMFS&C. A number of leading experts formed a consortium of medical centers that will be an integral part of the RDCRC. To support further its activities, additional infrastructure for this effort will include a formation of a rare disease office in each of the centers of the consortium, specialized laboratory testing sites, oversight of clinical trials, data management by the DTCC, and patient referral and education by the AAMDSIF. The IBMFS&C RDCRC and the consortium have developed a plan for educating fellows and community physicians about IBMFS&C. The success of these efforts will be evaluated in part by tracking referrals to the participating centers for standard treatment, or enrollment in the longitudinal and treatment protocols

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 描述（由申请人提供）：特发性骨髓衰竭状态和血细胞减少症（IBMFS&C）是一种罕见的疾病，其特征是造血祖细胞或干细胞衰竭，导致一种或所有血细胞谱系的产生不足。免疫病理生理学是所有这些疾病的许多情况下的统一因素。先前的合作试验已导致再生障碍性贫血（AA）的有效药物治疗的改善，但正在进行的多中心研究需要进一步推进AA的结果，特别是其他骨IBMFS，其中很少有有用的治疗选择存在。在这里，我们建议在克利夫兰诊所基金会（CCF）癌症中心成立IBMFS&C罕见病临床研究中心（RDCRC），包括几个专业中心，患者倡导小组和数据联盟，并与数据技术协调中心（DTCC）合作。IBMFS&C RDCRC将重点关注AA、阵发性睡眠性血红蛋白尿、单系血细胞减少症（包括大颗粒淋巴细胞白血病和纯红细胞再生障碍性贫血）以及各种骨髓增生异常综合征。该申请提出了一种多靶向方法来改善IBMFS&C的药物治疗，包括：1）为每个IBMFS实施定义护理标准的治疗算法，2）系统地评估可能提高诊断准确性或病理生理机制理解的新实验室测定，3）将患者纳入纵向随访研究以将新的和已建立的诊断变量与结果相关联，4）比较每种相关疾病的医疗和移植方法，5）为目前没有良好治疗选择或没有标准治疗方法的疾病子集开发实验治疗方案，6）培训博士后研究员为IBMFS&C开发临床试验和转化研究项目，7）教育社区医生诊断和管理IBMFS&C，8）与再生障碍性贫血和MDS国际基金会（AAMDSIF）合作，改善患者和医生的外展、教育和转诊资源。由于PI的专业知识，加上CCF CC的经验和规模，CCF独特地定位为IBMFS&C中的RDCRC。一些领先的专家组成了一个医疗中心联盟，将成为RDCRC的一个组成部分。为了进一步支持其活动，这一努力的额外基础设施将包括在联盟的每个中心建立一个罕见病办公室，专门的实验室检测站点，临床试验的监督，DTCC的数据管理，以及AAMDSIF的患者转诊和教育。IBMFS&C RDCRC和联盟已经制定了一项计划，用于教育研究员和社区医生关于IBMFS&C。这些努力的成功将部分通过跟踪转诊到参与中心进行标准治疗或纵向和治疗方案中的招募来评估